Judith Michels
Overview
Explore the profile of Judith Michels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grosse S, Genestie C, Scherier S, Maulard A, Pautier P, Leary A, et al.
Bull Cancer
. 2024 Nov;
112(3):335-339.
PMID: 39542783
Since the last FIGO classification in 2009, numerous studies and recommendations have contributed to improving the management of endometrial cancer. The introduction of molecular classification (including POLE, MMR, and P53...
2.
Sehouli J, Boer J, Brand A, Oza A, ODonnell J, Bennett K, et al.
Int J Gynecol Cancer
. 2024 Nov;
34(11):1677-1684.
PMID: 39496422
Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of...
3.
de la Calle-Fabregat C, Calafell-Segura J, Gardet M, Dunsmore G, Mulder K, Ciudad L, et al.
Sci Adv
. 2024 Sep;
10(38):eadq5226.
PMID: 39292770
Macrophages orchestrate tissue homeostasis and immunity. In the tumor microenvironment (TME), macrophage presence is largely associated with poor prognosis because of their reprogramming into immunosuppressive cells. We investigated the effects...
4.
Grau Bejar J, Yaniz Galende E, Zeng Q, Genestie C, Rouleau E, de Bruyn M, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 38955419
Background: Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking. Methods:...
5.
Blanc-Durand F, Camilleri G, Bayle A, Aldea M, Vasseur D, Ouali K, et al.
Cancer
. 2024 Jun;
130(19):3311-3320.
PMID: 38824658
Background: Molecular characterization has significantly improved the management of advanced endometrial cancer (EC). It distinguishes four molecular subclasses associated with prognosis and personalized therapeutic strategies. This study assesses the clinical...
6.
Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George M, et al.
Life Sci Alliance
. 2023 Oct;
7(1).
PMID: 37891002
We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ)...
7.
Kfoury M, Hazzaz R, Sanson C, Durand F, Michels J, Blameble E, et al.
Biomark Res
. 2023 Oct;
11(1):93.
PMID: 37858195
Genomic testing is crucial for the management of ovarian cancer. DNA from biopsies at diagnostic laparoscopies or interval debulking surgery after neoadjuvant chemotherapy, has a high failure rate. At relapse,...
8.
Borcoman E, Santana Dos Santos E, Genestie C, Pautier P, Lacroix L, Caputo S, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511329
Somatic/germline mutations (m)/(likely) pathogenic variants (PV) (/) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic , combined tumor-based...
9.
Blanc-Durand F, Tang R, Pommier M, Nashvi M, Cotteret S, Genestie C, et al.
Clin Cancer Res
. 2023 Apr;
29(16):3124-3129.
PMID: 37067532
Purpose: Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of BRCA1 promoter methylation to predict prognosis and HRD status remains unclear....
10.
Ouali K, Michels J, Blanc-Durand F, Leary A, Kfoury M, Genestie C, et al.
Bull Cancer
. 2023 Mar;
111(3):267-276.
PMID: 36863923
Although the management of epithelial ovarian cancer has evolved significantly over the past few years, it remains a public health issue, as most patients are diagnosed at an advanced stage...